CARDIFF, January 5, 2026 — Leads & Copy — Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) has announced the promotion of Fiona Sharp to Chief Financial Officer and Company Secretary, effective immediately. She has also been elected to the company’s Board of Directors.
Ms. Sharp joined Biodexa as Group Financial Controller in December 2019 and has since expanded her responsibilities to include many of those typically held by a CFO. Before joining Biodexa, she was Assistant Director of Finance for the Hywel Dda University Health Board, an organization with over 10,000 staff and a budget of approximately £800 million.
From 1999 until early 2018, Ms. Sharp held finance roles of increasing responsibility for Chime Communications Group, an international communications and sports marketing group with revenues of approximately £570 million. Chime Communications Group was listed on the UK stock exchange until it was bought out by private equity.
Stephen Stamp will relinquish his roles as Chief Financial Officer and Company Secretary but will remain as Chief Executive Officer.
Dr. Stephen Parker, Chairman of Biodexa, commented that Ms. Sharp has made significant contributions to the financial governance of the Group during her six years with the company. He added that her promotion is well-deserved, and that he and the other directors are looking forward to working with her on the Biodexa Board.
Biodexa Pharmaceuticals PLC, listed on NASDAQ: BDRX, is a clinical stage biopharmaceutical company developing innovative products for treating diseases with unmet medical needs. The company’s lead development programs include eRapa for Familial Adenomatous Polyposis and Non-Muscle Invasive Bladder Cancer; tolimidone for type 1 diabetes; and MTX110 for aggressive rare/orphan brain cancer indications.
eRapa is an oral capsule formulation of rapamycin, an mTOR inhibitor involved in regulating cellular metabolism, growth, and proliferation and activated during tumorigenesis.
Tolimidone is an orally delivered inhibitor of Lyn kinase, which is expressed in hematopoietic cells, neural tissues, liver, and adipose tissue. It demonstrates glycaemic control via insulin sensitization in animal models of diabetes.
MTX110 is a solubilized formulation of the HDAC inhibitor, panobinostat, delivered via convection-enhanced delivery (CED) directly to the tumor site, bypassing the blood-brain barrier and potentially avoiding systemic toxicity.
Biodexa is supported by three proprietary drug delivery technologies and is headquartered in Cardiff, UK.
For more information, please contact:
Biodexa Pharmaceuticals PLC
Stephen Stamp, CEO, CFO
Tel: +44 (0)29 20480 180
Source: Biodexa Pharmaceuticals PLC
